A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies
Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2014.11.529
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2015
Authors
Publisher
Elsevier BV